MARX Biotech Co., Ltd. (TPEX:7731)
Taiwan · Delayed Price · Currency is TWD 4.220
-0.040 (-0.94%)
Sep 9, 2026, 1:43 PM CST
MARX Biotech Revenue
MARX Biotech had revenue of 257.81M TWD in the half year ending June 30, 2026, with 20.32% growth. This brings the company's revenue in the last twelve months to 584.74M, down -17.97% year-over-year. In the year 2025, MARX Biotech had annual revenue of 635.85M with 2.85% growth.
Revenue (ttm)
584.74M
Revenue Growth
-17.97%
P/S Ratio
3.80
Revenue / Employee
n/a
Employees
80
Market Cap
2.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 635.85M | 17.63M | 2.85% |
| Dec 31, 2024 | 618.23M | 328.30M | 113.24% |
| Dec 31, 2023 | 289.93M | 179.28M | 162.04% |
| Dec 31, 2022 | 110.64M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 20.75B |
| MedFirst Healthcare Services | 8.06B |
| Syngen Biotech | 2.05B |
| Dynamic Medical Technologies | 1.40B |
| HeXun Biosciences | 308.21M |
| PhytoHealth | 143.43M |
| Caliway Biopharmaceuticals | 29.39M |
| Pell Bio-Med Technology | 28.93M |